Research programme: nuclear export inhibitors - Kosan

Drug Profile

Research programme: nuclear export inhibitors - Kosan

Alternative Names: CRM1 inhibitors - Kosan; KOS 2464; KOS-1815; KOS-2385

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Kosan Biosciences
  • Class
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (IV)
  • 27 Jun 2008 Kosan Biosciences has been acquired by Bristol-Myers Squibb
  • 10 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the pharmacokinetics, adverse events and Cancer pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top